Febrile neutropenia is having a fever of ≥38.3 ºC or ≥38 ºC over an hour and neutropenia that is having an absolute neutrophil count (ANC) of <500 neutrophils/mm3 or an ANC <1000 neutrophils/mm3 expected to decline to ≤500 neutrophils/mm3 over the next 48 hours.
The risk of febrile neutropenia is directly proportional to the duration and severity of neutropenia.
Fever is frequently the only indication of infection in the neutropenic patient.
New drug applications approved by US FDA as of 1 - 15 June 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Imipenem-cilastatin exhibited better efficacy than piperacillin-tazobactam as empiric antibiotic for febrile neutropaenia in haematopoietic stem cell transplantation (HSCT) recipients, based on a study.
Empirical cefepime monotherapy is associated with less economic strain and lower risk of serious adverse or toxic effects of multidrug combinations compared with piperacillin-tazobactam in paediatric febrile neutropaenia patients, as shown in a study.
High-dose intravenous cefepime 2 g every 8 hours may impart adequate antibiotic exposure if the pathogen has ≤ 4 mg/liter MIC in febrile neutropaenic patients with haematological malignancies and normal renal function, as presented in a study.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Infectious Diseases - Malaysia digital copy today!
Results of a study conducted by the Chinese University of Hong Kong (CUHK) revealed that patients who recovered from hepatitis B virus (HBV) infection are still at risk for hepatocellular carcinoma (HCC).
A US study suggests that expanding HIV screening to reduce undiagnosed infections and increasing access to care and treatment to achieve viral suppression are important to lessen HIV transmission. It is also imperative that prevention methods, such as condoms and pre-exposure prophylaxis, be easily accessed, particularly among young men who have sex with men (MSM) and MSM of colour.